Cell Resources Inc. Launches New Stem Cell Options for Regenerative Medicine Research

Cell Resources Inc. Launches New Stem Cell Options for Research

Cell Resources Inc., a subsidiary based in Chiyoda, Tokyo, has initiated the provision of mesenchymal stem cells (MSCs) derived from human umbilical cords and amniotic membranes. This marks an important development in the field of regenerative medicine, enhancing the repertoire of options available for researchers engaged in the development of regenerative medical products and related research.

Background and Objective

Mesenchymal stem cells are a diverse group of cells found in various tissues, including bone marrow and adipose tissue. They possess the remarkable ability to differentiate into multiple cell types (a feature known as multipotency), making them a focal point for applications in numerous diseases. Notably, MSCs sourced from human umbilical cords and amniotic membranes have attracted considerable attention due to their high proliferation capacity and the non-invasive manner in which they can be harvested.

Despite the promising potential of MSCs, the stable supply of human cell materials has been recognized as a challenge in the advancement of regenerative medical products and adjacent industries in Japan. The Alfresa Group, which serves as an essential infrastructure for the stable supply of pharmaceuticals, aims to construct a comprehensive total supply chain service for regenerative medicine, providing everything from raw material sourcing to delivery to healthcare institutions.

Cell Resources is contributing to this goal by offering domestically sourced cell materials and manufacturing cell derivatives. The company has established partnerships with both domestic and international alliance partners to create a consolidated Contract Development and Manufacturing Organization (CDMO) service system, thereby supporting the commercialization of cell therapies through the social implementation of regenerative medical products.

The new cell line is being produced at the Koriyama Cell Processing Center, which is the company’s cell culture processing facility designed for developing regenerative medicine products, research reagents, and automated culture systems.

Overview of the New Product

The MSCs are only available for research applications and will require an evaluation based on intended use as well as the signing of a Material Transfer Agreement (MTA). These cells can be purchased through existing transaction routes established with Kanto Chemical Co., Ltd., a company with a strong transaction base across universities, research institutions, and life sciences companies. Additionally, Alfresa Shinohara Chemical Co., Ltd., a group subsidiary that operates a sales and logistics network in the Shikoku region, will also serve as a partner for sales.

Features of the Product

1. Domestic Production: The MSCs are manufactured at the Koriyama Cell Processing Center, which has obtained specific cell processing permissions and uses fetal tissue sourced with consent from donors within Japan.
2. Proliferation Ability: The cells can be cultured to enable stable increases in cell numbers.
3. Gender Information of Specimens: When providing these cells, the company discloses the gender information of the fetal materials used, allowing researchers to select cells according to their study needs. Importantly, the data regarding the fetal specimens is handled in such a way that individual identities are not disclosed to Cell Resources.

Future Prospects

While the immediate impact of this initiative on the company’s performance is expected to be minimal, it is viewed as a significant step toward enhancing the overall corporate value of the group in the medium to long term. Should any important revelations arise concerning this initiative, the company pledges to communicate them promptly.

For inquiries about purchasing this product, potential customers can access the Cell Resources inquiry page. For media inquiries, they can contact the Corporate Communication Department of Alfresa Holdings Co., Ltd.